Royalty Pharma plc Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax
Royalty Pharma plc (RPRX) reported Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-15.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax · last filed 2023-02-15
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2021-12-31 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2021-09-30 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2021-06-30 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2022 was $0.00.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2020 was $4.07M, a 34.30% decline from fiscal 2019.
- Royalty Pharma plc other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2019 was $6.19M, a 22.67% decline from fiscal 2018.
| Period end | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 3 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 6 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 9 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $0.00 10-K · filed 2023-02-15 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $0.00 derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $0.00 derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $4.07M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $4.07M 10-Q · filed 2021-11-10 | $5.44M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-11 | $4.07M 10-Q · filed 2021-08-11 | $5.44M derived: sum of 3 quarters · filed 2022-02-15 | $7.07M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $4.07M 10-Q · filed 2021-05-11 | $5.44M derived: sum of 2 quarters · filed 2022-02-15 | $7.07M derived: sum of 3 quarters · filed 2022-02-15 | $8.67M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $3.00M derived: sum of 2 quarters · filed 2022-02-15 | $4.60M derived: sum of 3 quarters · filed 2022-02-15 | $6.19M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.62M 10-Q · filed 2020-11-12 | $3.22M derived: sum of 2 quarters · filed 2020-11-12 | $4.81M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-12 | $3.19M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $8.00M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |